Micellar formulations of Crizotinib and Dasatinib in the management of glioblastoma multiforme.

摘要: Glioblastoma multiforme (GBM) defies the currently practiced management of radiotherapy, chemotherapy and surgery hence, it is associated with a high fatality rate median survival 14.6 months. In our previous work investigating different tyrosine kinase inhibitors (TKIs), we established that combination Crizotinib Dasatinib exerted most potent effect on GBM cell lines. this work, to improve targeted therapy at site tumour avoid systemic toxicity, exploited enhanced permeability retention by designing micellar formulations these two TKIs. were successfully encapsulated in poly(styrene-co-maleic acid) (SMA) micelles which then evaluated for their physicochemical characteristics, anti-proliferative effect, mode death, efficacy spheroid models, signalling, antiangiogenic potential vivo anticancer activity. Our results showed had induced four lines grown as monolayer spheroid. The was also efficacious vitro models angiogenesis vascular mimicry. data activity TKIs compared free drugs. conclusion, proved carry promising warrant further investigation.